HIV Manifestations of Posterior Segment
The introduction of highly active antiretroviral therapy (HAART) has significantly reduced the incidence and prevalence of HIV-related ocular morbidity. Still, cytomegalovirus (CMV) retinitis is considered the major cause of visual loss in HIV-infected individuals. Timely suspicion and prompt comprehensive evaluation is essential to reach a clinical diagnosis and initiate the required treatment. Taking into consideration other infrequent pathologies that may affect immunocompromised individuals, and management of emerging drug resistance and complications, may improve the final visual outcome.
KeywordsHuman Immunodeficiency Virus Visual Acuity Posterior Segment Cryptococcal Meningitis Retinitis Cytomegalovirus
- David SB, et al. Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol. 2002;133:484–98.Google Scholar
- Douglas J, et al. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. New Engl J Med. 1992; 326:213–20.Google Scholar
- Feinberg JE, et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study G. J Infect Dis. 1998;177:48–56.CrossRefPubMedGoogle Scholar
- Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Am J Ophthalmol. 1997; 124:141–57.Google Scholar
- Richard AL, et al. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Archiv Int Med. 1995;155:65–74.Google Scholar